论文部分内容阅读
目的:研究口服重组人Ⅱ型胶原250-270多肽(CⅡ250-270)对胶原诱导性关节炎(CIA)小鼠特异性体液免疫反应的抑制作用,为应用口服CⅡ250-270治疗类风湿关节炎提供理论依据。方法:ELISA测定加强免疫后小鼠血清中抗原特异性抗体的表达,ELISPOT检测小鼠脾脏淋巴细胞中抗原特异性抗体形成细胞。结果:口服重组人CⅡ250-270小鼠血清中抗CⅡ和抗CⅡ250-270的IgG抗体水平[A值分别为(0.82±0.02)、(0.84±0.04)]比CⅡ免疫对照组[抗CⅡ的IgG抗体水平,A值为(1.01±0.06)]显著降低,而且特异性抗CⅡ250-270的IgG抗体反应在口服多肽组被明显抑制(P<0.01);口服重组人CⅡ250-270小鼠的CⅡ和CⅡ250-270特异性抗体形成脾细胞的增殖频率分别为(158±9计数/孔)、(181±10计数/孔),比CⅡ免疫对照组[CⅡ特异性抗体形成脾细胞的增殖频率为(247±16计数/孔)]也显著减少(P<0.05)。结论:口服重组人CⅡ250-270多肽具有抑制CIA小鼠的特异性体液免疫的作用,可能是此疗法治疗CIA多发性关节炎的重要机制。
OBJECTIVE: To study the inhibitory effect of oral recombinant human collagen type 250-270 (CⅡ250-270) on the specific humoral immune response in collagen-induced arthritis (CIA) mice and to provide a method for the treatment of rheumatoid arthritis with oral CⅡ250-270 Theoretical basis. Methods: The expression of antigen-specific antibody in the serum of mice after immunization was detected by ELISA. Antigen-specific antibody-forming cells were detected by ELISPOT in splenic lymphocytes of mice. Results: The serum levels of anti-CⅡ and anti-CⅡ250-270 in serum of oral recombinant human CⅡ250-270 mice [A (0.82 ± 0.02), (0.84 ± 0.04)] were significantly higher than those of CⅡ immunized mice (1.01 ± 0.06)], and the IgG antibody response against specific CⅡ250-270 was significantly inhibited in the oral polypeptide group (P <0.01). The level of CⅡ in oral recombinant human CⅡ250-270 mice The frequency of proliferation of splenocytes from CⅡ250-270-specific antibody was (158 ± 9 counts / well), (181 ± 10 counts / well), respectively. 247 ± 16 counts / well)] was also significantly reduced (P <0.05). Conclusion: Oral recombinant human CⅡ250-270 peptide can inhibit the specific humoral immunity of CIA mice, which may be an important mechanism of this therapy for CIA.